Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Inselspital offers a new form of therapy for leukemia and lymphoma

09.11.2018

On 22 October 2018, an innovative new immunotherapy was approved in Switzerland for the treatment of relapses of acute leukemias and lymphomas. Since this week, the Inselspital is the first hospital in Switzerland to be able to offer this new treatment.

A milestone in cancer therapy: For the first time, patients in Switzerland who suffer from relapsed acute lymphoblastic leukemia or malignant lymphomas can received a personalized form of immunotherapy.


Microscopic view of a T cell (Tumor immunology and cancer stem cells lab)

Department for BioMedical Research, University of Bern

Since approval on 22 October 2018, the Inselspital is the first center in Switzerland to be able to offer this new therapy. The treatment is restricted to to young adults with relapsed acute lymphoblastic leukemias and adults with relapsed and refractory aggressive lymphomas.

Fighting cancer with your own immune system

"Previous immunotherapies stimulate the body's own defenses which is not particularly targeted," explains PD Dr. med. Urban Novak from the Inselspital. "The new therapy enables the patient’s immune cells to recognize and destroy tumor cells This takes us a step closer to a precise and truly personalized treatment."

The malignant cells of these patients are resistant to most of the treatments currently used against cancer. This explains the high expectations on this new treatment strategy.

The CAR-T therapy utilizes the body's own modified immune cells (so-called CAR-T cells). These cells are taken from the patient, genetically engineered outside the body to enable them to attack the cancer cells and retransfused.

A center with considerable experience

By applying the first approved "living drug", the Inselspital is entering groundbreaking territory. Only a few clinics around the world have used it in studies.

The manufacturer has chosen to gradually introduce the treatment in Switzerland in a limited number of cancer centers that are very experienced in treating leukemias and lymphoma.

At the Inselspital in Bern, the Department of Medical Oncology and the Department of Hematology and Central Hematological Laboratory will jointly be conducting the CAR-T collection, transfusion and treatment.

Because the drug is currently administered in an inpatient setting, the multidisciplinarly teams can respond quickly if there are signs of side effects. These may include an overreaction of the immune system, temporary neurological failures or infections. Cancer therapies are often extremely strenuous for the patient, and as a rule they are only used in cases where the benefits clearly outweigh the potential risks.

Research for more targeted cancer therapies

The Inselspital is highly committed to the research of immunotherapy against cancer. In work that has been underway since 2003 under Head Physician and Director of the Department of Medical Oncology, Prof. Dr. Med. Adrian Ochsenbein, the oncological team has been researching potential new approaches in the treatment of leukemia in a laboratory specialized for tumor immunology.

Currently the Inselspital is also the only Swiss center participating in an international study examining the potential of another CAR-T cell construct for treatment of relapsed aggressive lymphomas.

Immunotherapy for leukemia, lymphoma and solid tumors, the personalized and targeted treatment of cancer are all important research priorities at the University Cancer Center (Tumorzentrum Bern). The Inselspital is the largest center for autologous stem-cell transplantation in Switzerland. This area of focus is being consistently advanced with the new CAR-T therapy.

Competence Center for Cancer Therapy at Inselspital Bern

Tumorzentrum Bern – also known as the University Cancer Center Inselspital (UCI) – offers comprehensive advice, treatment and care to cancer patients and their relatives. Thanks to the cooperation of highly qualified experts from all disciplines, optimal care is ensured at all stages of cancer therapy.

The interdisciplinary Tumor Boards form a central element of treatment. All the involved experts jointly discuss treatment options and determine the best possible therapy in consultation with the patients.

Support includes therapy for pain and physiotherapy, palliative care or psychological and pastoral care as part of the comprehensive offer for patients. Tumorzentrum Bern also focuses on further developing existing treatment options for various tumor-based conditions. As such it is involved in research at both the national and international levels.

Wissenschaftliche Ansprechpartner:

PD. Dr. med. Urban Novak, Chief Physician, Department of Medical Oncology, Tumorzentrum Bern, Inselspital, University Hospital Bern, Urban.Novak@insel.ch.

Weitere Informationen:

Inquiries regarding the assignment of patients: onkologie@insel.ch
(recurrent leukemia 18-25 years, recurrent lymphoma in adults)

http://www.insel.ch

Monika Kugemann | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht When predictions of theoretical chemists become reality
22.05.2020 | Technische Universität Dresden

nachricht From artificial meat to fine-tuning photosynthesis: Food System Innovation – and how to get there
20.05.2020 | Potsdam-Institut für Klimafolgenforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: I-call - When microimplants communicate with each other / Innovation driver digitization - "Smart Health“

Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.

When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

Im Focus: NASA's Curiosity rover finds clues to chilly ancient Mars buried in rocks

By studying the chemical elements on Mars today -- including carbon and oxygen -- scientists can work backwards to piece together the history of a planet that once had the conditions necessary to support life.

Weaving this story, element by element, from roughly 140 million miles (225 million kilometers) away is a painstaking process. But scientists aren't the type...

Im Focus: Making quantum 'waves' in ultrathin materials

Study co-led by Berkeley Lab reveals how wavelike plasmons could power up a new class of sensing and photochemical technologies at the nanoscale

Wavelike, collective oscillations of electrons known as "plasmons" are very important for determining the optical and electronic properties of metals.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

Inexpensive retinal diagnostics via smartphone

25.05.2020 | Medical Engineering

Smart machine maintenance: New AI system also detects unknown faults

25.05.2020 | Information Technology

Artificial Intelligence for optimized mobile communication

25.05.2020 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>